LEO Pharma / Astellas Pharma merger inquiry
The CMA investigated the anticipated acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas).
Statutory timetable
| Phase 1 dates | Action |
|---|---|
| 5 April 2016 | Decision published |
| 11 March 2016 | Decision announced |
| 22 January 2016 | Launch of merger inquiry |
| 22 January to 5 February 2016 | Invitation to comment |
Phase 1
CMA clearance decision
11 March 2016: The CMA has cleared the acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas). The full text of the decision is available below.
- (5.4.16)
Launch of merger inquiry
22 January 2016: The CMA announced the launch of its merger inquiry by notice to the parties.
- (22.1.16)
Invitation to comment: Now closed
22 January 2016: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Contact
Please send written representations about any competition or public interest to:
Tobe Nwaogu
Competition and Markets Authority
Victoria House
37 Southampton Row
London
WC1B 4AD
Updates to this page
-
Full text of the decision published.
-
Clearance decision announced.
-
First published.